ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Roche pays Vividion $135 million for protein degradation

by Ryan Cross
May 21, 2020 | APPEARED IN VOLUME 98, ISSUE 20

 

Roche has formed a partnership with the targeted protein degradation start-up Vividion Therapeutics. Part of the partnership’s focus will be finding compounds that target new E3 ligases, a family of proteins that drag other proteins off for degradation. That will give the companies tools for selectively degrading proteins linked to cancer and immune diseases. Vividion will get $135 million in cash and potentially billions more in milestone payments. Vividion was founded by three chemists from Scripps Research Institute: Benjamin Cravatt, Phil Baran, and Jin-Quan Yu.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment